• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

OrbusNeich 完全可吸收冠状动脉支架平台,采用双层分区涂层。

OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings.

机构信息

Department of Advanced Research and Development, OrbusNeich Medical, Inc. 5363 NW 35th Ave, Fort Lauderdale, FL 33309, USA.

出版信息

EuroIntervention. 2009 Dec 15;5 Suppl F:F65-71. doi: 10.4244/EIJV5IFA11.

DOI:10.4244/EIJV5IFA11
PMID:22100679
Abstract

The field of stent based tissue engineering continues to revolutionise modern medicine by designing novel materials to restore vascular tissue function. Accordingly, the following discussion examines a novel, absorbable, polymeric scaffold engineered in combination with dual therapeutic coating, enabling locally administered temporary scaffolding in the coronary arteries for long term vascular patency and repair. This coronary stent platform consists of an absorbable polymeric material stent structure that incorporates a dual partitioned coating, by means of pro-healing EPC (endothelial progenitor cell) capture technology allowing for rapid endothelial coverage, and an absorbable polymer matrix with sustained elution of sirolimus, a drug controlling neointimal proliferation. This paper provides a brief overview of the various innovations developed by OrbusNeich to create this fully absorbable coronary device platform.

摘要

支架基组织工程领域通过设计新型材料来恢复血管组织功能,继续推动现代医学的发展。因此,下面的讨论探讨了一种新型的、可吸收的聚合物支架,该支架与双治疗涂层相结合,可在冠状动脉内提供局部临时支架,以实现长期血管通畅和修复。这个冠状动脉支架平台由一个可吸收聚合物材料支架结构组成,该结构采用了双分区涂层,通过促进愈合的内皮祖细胞(endothelial progenitor cell,EPC)捕获技术,实现快速内皮覆盖,以及含有西罗莫司的可吸收聚合物基质,持续洗脱西罗莫司,以控制新生内膜增殖。本文简要介绍了 OrbusNeich 公司为创建这个完全可吸收冠状动脉器械平台而开发的各种创新技术。

相似文献

1
OrbusNeich fully absorbable coronary stent platform incorporating dual partitioned coatings.OrbusNeich 完全可吸收冠状动脉支架平台,采用双层分区涂层。
EuroIntervention. 2009 Dec 15;5 Suppl F:F65-71. doi: 10.4244/EIJV5IFA11.
2
A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.一项前瞻性随机研究,使用光学相干断层扫描评估冠状动脉依维莫司洗脱支架与紫杉醇洗脱球囊后扩张的金属裸支架在植入后 6 个月时的内皮覆盖和新生内膜增殖情况(OCTOPUS 试验):原理、设计和方法。
EuroIntervention. 2011 May;7 Suppl K:K93-9. doi: 10.4244/EIJV7SKA16.
3
Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.涂层生物吸收和慢性裸金属支架与完全生物可吸收支架。
EuroIntervention. 2009 Dec 15;5 Suppl F:F36-42. doi: 10.4244/EIJV5IFA6.
4
Everolimus-eluting bioabsorbable stent--Abbot Vascular programme.依维莫司洗脱生物可吸收支架——雅培血管介入项目
EuroIntervention. 2009 Dec 15;5 Suppl F:F98-F102. doi: 10.4244/EIJV5IFA17.
5
Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.紫杉醇和西罗莫司对内皮祖细胞和冠状动脉平滑肌细胞的生长和迁移有不同的影响。
EuroIntervention. 2011 May;7 Suppl K:K32-42. doi: 10.4244/EIJV7SKA6.
6
Assimilating the current clinical data of fully bioabsorbable stents.汇总全生物可吸收支架的当前临床数据。
EuroIntervention. 2009 Dec 15;5 Suppl F:F103-8. doi: 10.4244/EIJV5IFA18.
7
Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries.通过阳离子电沉积涂层技术制备纳米颗粒洗脱支架:经生物可吸收聚合物纳米颗粒洗脱支架在猪冠状动脉中实现高效纳米药物递送
JACC Cardiovasc Interv. 2009 Apr;2(4):277-83. doi: 10.1016/j.jcin.2008.08.023.
8
Local drug delivery for treatment of coronary and peripheral artery disease.局部药物输送治疗冠状动脉和外周动脉疾病。
Cardiovasc Ther. 2011 Dec;29(6):e54-66. doi: 10.1111/j.1755-5922.2010.00187.x. Epub 2010 Jun 11.
9
Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.新发冠状动脉病变高危再狭窄患者中内皮祖细胞捕获支架与 Taxus Liberté 支架的两年随访:一项随机、单中心、先导研究。
Catheter Cardiovasc Interv. 2011 Aug 1;78(2):189-95. doi: 10.1002/ccd.23143. Epub 2011 Jul 15.
10
Elixir Medical's bioresorbable drug eluting stent (BDES) programme: an overview.伊莱克斯医疗公司的生物可吸收药物洗脱支架(BDES)项目概述。
EuroIntervention. 2009 Dec 15;5 Suppl F:F80-2. doi: 10.4244/EIJV5IFA13.

引用本文的文献

1
Coating Techniques and Release Kinetics of Drug-Eluting Stents.药物洗脱支架的涂层技术与释放动力学
J Med Device. 2019 May 4;10(1). doi: 10.1115/1.4031718. Epub 2015 Nov 5.
2
Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease.生物可吸收支架:冠心病治疗的当前证据
J Clin Diagn Res. 2016 Oct;10(10):OE01-OE07. doi: 10.7860/JCDR/2016/21915.8429. Epub 2016 Oct 1.
3
Bioresorbable scaffolds in the treatment of coronary artery disease.生物可吸收支架在冠状动脉疾病治疗中的应用
Med Devices (Auckl). 2013 Mar 12;6:37-48. doi: 10.2147/MDER.S22547. Print 2013.
4
Bioresorbable scaffolds: current evidence and ongoing clinical trials.生物可吸收支架:当前证据和正在进行的临床试验。
Curr Cardiol Rep. 2012 Oct;14(5):626-34. doi: 10.1007/s11886-012-0295-5.